Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 5:14:2981-2987.
doi: 10.2147/NDT.S176455. eCollection 2018.

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Raul Escamilla  1 , Beatriz Camarena  2 , Ricardo Saracco-Alvarez  1 , Ana Fresán  3 , Sandra Hernández  2 , Alejandro Aguilar-García  2
Affiliations
Free PMC article

Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia

Raul Escamilla et al. Neuropsychiatr Dis Treat. .
Free PMC article

Abstract

Purpose: The efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: COMT (Val158Met), DRD2 (A-241G, C376G, C939T, Taq1A), and DRD3 (Ser9Gly).

Patients and methods: We classified the patients through a retrospective/prospective methodology to define response phenotypes.

Results: COMT/Val158Met and DRD3/Ser9Gly were associated with the responder group (P<0.05). The single-nucleotide polymorphism A-241G of DRD2 gene was related with the resistant-to-treatment group (P<0.001). Finally, Met/Met of COMT and Ser/Gly of DRD3 genes showed a predictive effect associated with the resistant-to-treatment phenotype.

Conclusion: Further analyses should be performed to validate these genetic markers as mediators for the response to APs.

Keywords: dopamine; pharmacogenetics; resistant to treatment; ultraresistant to treatment.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388(10039):86–97. - PMC - PubMed
    1. Mandelli L, Toscano E, Porcelli S, Fabbri C, Serretti A. Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. Psychiatry Investig. 2016;13(2):247–249. - PMC - PubMed
    1. Stahl SM, Morrissette DA, Citrome L, et al. “Meta-guidelines” for the management of patients with schizophrenia. CNS Spectr. 2013;18(3):150–162. - PubMed
    1. Hoyer C, Kranaster L, Leweke FM, Klosterkötter J, Meyer-Lindenberg A, Koethe D. Familial differential treatment response in schizophrenia – lessons from a case of three affected siblings. Pharmacopsychiatry. 2010;43(5):196–197. - PubMed
    1. Marković J, Plestic S, Kostic J. Concordant response to pharmacotherapy in monozygotic twins with schizoaffective disorder. Eur Rev Med Pharmacol Sci. 2013;17(23):3262–3264. - PubMed